Epilepsy Study Consortium Inc
- Assets
- $3.5m
- Revenue
- $3.4m
- Investments
- $1.0m
- Employees
- 7
- Location
- Reston, VA
- Founding
- 05/2007
- Data as of
- 12/2023
- EIN
- 20-4950952
Organization Overview
Epilepsy Study Consortium Inc is located in Reston, VA. The organization was established in 2007. According to its NTEE Classification (G54) the organization is classified as: Epilepsy, under the broad grouping of Voluntary Health Associations & Medical Disciplines and related organizations. As of 12/2023, Epilepsy Study Consortium Inc employed 7 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Epilepsy Study Consortium Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Epilepsy Study Consortium Inc generated $3.4m in total revenue. This represents relatively stable growth, over the past 9 years the organization has increased revenue by an average of 8.5% each year. All expenses for the organization totaled $1.7m during the year ending 12/2023. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
ACCELERATING THE DEVELOPMENT OF NEW THERAPIES IN EPILEPSY TO IMPROVE PATIENT CARE THROUGH RESEARCH.
Describe the Organization's Program Activity:
Part 3 - Line 4a
CONSULTING - MADE AVAILABLE VAST EPILEPSY EXPERTISE WHICH WAS UTILIZED FOR ADVISORY BOARDS AND INDEPENDENT CONSULTING ACTIVITY. PROVIDED STUDY DESIGN CONSULTATION ON A NUMBER OF PROTOCOLS. DEVELOPED AND IMPLEMENTED EDUCATIONAL TOOLS FOR USE IN CLINICAL TRIALS TO ENSURE ENROLLMENT OF APPROPRIATE SUBJECTS. CENTRAL REVIEW OF DOCUMENTATION TO CONFIRM ELIGIBILITY FOR PATIENTS IN CLINICAL TRIALS. DEVELOPED SEVERAL PROOF OF PRINCIPLE PROTOCOLS WHICH ARE AVAILABLE TO CLIENTS. IMPLEMENTED THE PREVIOUSLY DESIGNED PROOF OF PRINCIPLE STUDY TO ASSESS PHOTOSENSITIVE EPILEPSY INCLUDING SITE TRAINING.
HUMAN EPILEPSY PROJECT - CONTINUING TO ANALYZE DATA FROM HEP 1 & HEPS 2 STUDIES. OVERSEE AND COORDINATE THE FINANCIAL ASPECTS OF THE HEP3 STUDY. TESC MANAGES HEP3 STUDYS LIFE CYCLE FOR NYU, OVERSEES AND COORDINATES FINANCIAL ASPECTS OF THE STUDY AND THE PARTICIPATING SITES.
TRIAL DESIGNS - PREPARE AND ORGANIZE MULTINATIONAL SYMPOSIUM ON EPILEPSY TRIAL DESIGN AND IMPLEMENTATION.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Michael Sperling MD Director | Trustee | 1 | $0 |
Bree Diventura Co-Executive Director | OfficerTrustee | 40 | $194,484 |
Gregory Krauss MD Director | Trustee | 1 | $0 |
John Pollard MD Director | Trustee | 1 | $0 |
Pavel Klein MD Director | Trustee | 1 | $0 |
Sudha Kessler MD Director | Trustee | 1 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $855,830 |
| Noncash contributions included in lines 1a–1f | $10,131 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $855,830 |
| Total Program Service Revenue | $2,473,596 |
| Investment income | $37,668 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $4,704 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $3,371,798 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $66,000 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $364,789 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $347,581 |
| Pension plan accruals and contributions | $17,464 |
| Other employee benefits | $2,308 |
| Payroll taxes | $51,184 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $10,033 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $134,563 |
| Advertising and promotion | $0 |
| Office expenses | $24,567 |
| Information technology | $16,368 |
| Royalties | $0 |
| Occupancy | $3,344 |
| Travel | $21,867 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $210,849 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $34,437 |
| All other expenses | $0 |
| Total functional expenses | $1,701,465 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $2,416,677 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $1,037,501 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $3,454,178 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Net assets without donor restrictions | $3,454,178 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $3,454,178 |
Grants Awarded
Over the last fiscal year, Epilepsy Study Consortium Inc has awarded $400,576 in support to 3 organizations.
| Grant Recipient | Amount |
|---|---|
NYU SCHOOL OF MEDICINE PURPOSE: GENERAL SUPPORT | $342,612 |
CHILDREN'S HOSPITAL OF PHILADELPHIA RESEARCH INSTITUTE PURPOSE: GENERAL SUPPORT | $41,929 |
AMERICAN EPILEPSY SOCIETY PURPOSE: GENERAL SUPPORT | $16,035 |